Acarbose is again on the stage

查看全文 作　　者：Mustafa [1]Altay

机构地区：[1]Department of Endocrinology and Metabolism,University of Health Sciences Turkey,Keçiören Health Administration and Research Center,Keçiören 06290,Ankara,Turkey

出　　处：《World Journal of Diabetes》索引2022年第13卷第1期,共4页

摘　　要：Acarbose is an agent that has been used to treat type 2 diabetes for about 30 years;it prevents postprandial hyperglycemia by inhibiting carbohydrate digestion in the small intestine.Since incretin-based treatments have been preferred over the last 10 to 15 years,the use of acarbose is not as common in treating type 2 diabetes as before.Some studies have shown that acarbose also produces a weight-loss effect by increasing glucagon-like peptide 1(GLP-1).The positive effect of acarbose on GLP-1,and increasing evidence that it provides cardiovascular protection,suggests that acarbose may again be considered among the first-choice antidiabetic agents,as it was in the 1990s. 关键词：ACARBOSE Cardiovascular protection Glucagon-like peptide 1 OBESITY Waist-to-height ratio

相关文献

参考文献（13）
引证文献（2）
耦合文献（0）

参考文献(13)

引证文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Acarbose is again on the stage

参考文献(13)

引证文献(2)

用户提示